Aminex Therapeutics Initiates First Clinical Trial of Novel Immunotherapy AMXT 1501 + DFMO in Cancer Patients
Polyamine depletion therapy represents a unique cancer immunotherapy approach
Aminex Therapeutics, Inc., a clinical-stage drug development company focused on advanc...





